New vaccine support (NVS) for HPV
GAVI’s support for new vaccines presents an opportunity for countries to not only implement vaccines that protect against diseases causing substantial morbidity and/or mortality, but also to build upon the vaccine investments in order to increase immunisation coverage rates, and strengthen routine immunisation services and primary health care systems. In line with a 2009 WHO position paper on cervical cancer recommending that routine human papillomavirus (HPV) vaccination be included in national immunisation programmes, GAVI provides support to eligible countries for HPV vaccines that protect against types 16 and 18, responsible for causing about 70% of cervical cancer cases. The form of support provided by GAVI depends on the level of demonstrated ability in a country to deliver vaccines to young adolescent girls. Countries that have demonstrated the ability may apply for GAVI support for nationwide introduction of HPV vaccines.
- Project ID
47122-1920-LBR-19B-X- Activity status
- 2 - Implementation
- Aid type
- B02 - Core contributions to multilateral institutions
- % to Liberia
- 100.00
Organisations
- Funding
- The Global Alliance for Vaccination and Immunisation
- Extending
- World Health Organisation - core voluntary contributions account (for technical assitance)
- Accountable
- Federal States & Local Governments
- Implementing
- Federal States & Local Governments
- Extending
- United Nations Childrens Fund
Disbursements by fiscal year, quarter
| Fiscal year |
Fiscal quarter |
Value (USD) |
Liberia Value (USD) |
Commitments by fiscal year, quarter
| Fiscal year |
Fiscal quarter |
Value (USD) |
Liberia Value (USD) |
| 2018 |
Q2 |
584,500.00 |
584,500.00 |
MTEF projections by fiscal year
| Fiscal year |
Value (USD) |
Liberia Value (USD) |
| 2020 |
240,000.00 |
240,000.00 |
| 2019 |
532,250.00 |
532,250.00 |
| 2018 |
292,250.00 |
292,250.00 |
| CRS code |
% |
|
Infectious disease control
(12250)
|
100.0
|